Living with DMD: Inspiring each other’s futures
Santhera is putting patient needs at the heart of its rare disease speciality business. Chief Executive Officer Thomas Meier, PhD, talks about the company’s mission – and how rationalising Europe’s drug review systems could help patients.
Progress in health and social care in European countries is helping many boys with Duchenne muscular dystrophy (DMD) to extend their lives beyond what was once dreamed possible, and to take control of their lives as they grow up and become men.
Company says it will listen to concerns of patient advocates
The top 10 pharma milestones of the year to date.
Review of marketing authorisation delayed, new trial likely.